ARN-6039 is under clinical development by Signalexis and currently in Phase I for Neuromyelitis Optica (Devic’s Syndrome). According to GlobalData, Phase I drugs for Neuromyelitis Optica (Devic’s Syndrome) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ARN-6039’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BOS-172767 (ARN-6039) is under development for the treatment of solid tumor, melanoma, pancreatic cancer, multiple sclerosis, psoriasis and neuromyelitis optica (NMO). It is administered through oral route as a capsule and tablet. It is a new chemical entity. The drug candidate targets retinoic acid-related orphan nuclear receptor gamma t (RORgt). It is developed based on the Fragment-Field Drug Design (FFDD) based technology.
Signalexis is a biotechnology company engaged in research and development of novel small molecule therapeutics for the treatment of solid tumors. The company is headquartered in American Fork, Utah, the US.
For a complete picture of ARN-6039’s drug-specific PTSR and LoA scores, buy the report here.